Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Glehr, M; Leithner, A; Scheipl, S; Zacherl, M; Quehenberger, F; Maurer-Ertl, W; Gruber, G; Beham, A; Windhager, R.
Liposarcomas: treatment and outcome, a retrospective single-center study
EUR SURG. 2009; 41(4): 163-169.
Doi: 10.1007/s10353-009-0477-6
Web of Science
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
-
Glehr Mathias
- Co-Autor*innen der Med Uni Graz
-
Beham Alfred
-
Gruber Gerald
-
Leithner Andreas
-
Maurer-Ertl Werner
-
Quehenberger Franz
-
Scheipl Susanne
-
Windhager Reinhard
-
Zacherl Maximilian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: In liposarcoma (LS), tumor-grade, histopathologic subtype, size, and completeness of resection are important prognostic factors. METHODS: We analyzed 80 patients with LS in an unselected patient sample concerning local recurrence, metastases, and survival in relation to clinicopathological characteristics and treatment. RESULTS: The five-year event-free rate was 82%. The strongest predictive prognostic factor was tumor grading. There was a significant influence of age over 60 showing a worse prognosis. Within 5 years after diagnosis, metastases were diagnosed in 13.1% (95% CI from 2.9% to 22.2%). The mean interval from first diagnosis to metastases was 27 months (0 to 63 months). Local recurrence occurred just in patients, who were not primary treated in a tumor-center and first resection was inadequate (five LS G II and one LS G I). CONCLUSIONS: Prognosis of LS is good if surgical treatment is adequate and resection performed with clear margins. Patients with suspected LS should be referred to specialized tumor-centers.
- Find related publications in this database (Keywords)
-
Liposarcoma
-
lipomatous tumor
-
soft tissue sarcoma
-
radiation
-
chemotherapy